NATCO Announces . Launch of First Generic Version of Nexavar® (Sorafenib) Tablets in the U.S. Market
2022-06-02 · NATCO Pharma Ltd. · original natcopharma.co.in ↗
NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce the launch of the first generic version of Nexavar® (Sorafenib) Tablets in 200 mg strength today in the U.S. market. The product will be launched by NATCO’s commercial partner Viatris, a global pharmaceutical company. Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC). For more information refer to the full prescribing information or other medical resources. Nexavar® registered sales of USD 69.7 million for the year ending December 2021 as per industry sales data. Nexavar ® is a registered trademark of Bayer Healthcare Pharmaceuticals Inc. All brand names and trademarks are the property of their respective owners.
The release as fetched from its publisher. natcopharma.co.in ↗